Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does NIRSEVIMAB-ALIP Cause Product prescribing issue? 6 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 6 reports of Product prescribing issue have been filed in association with NIRSEVIMAB-ALIP. This represents 0.8% of all adverse event reports for NIRSEVIMAB-ALIP.

6
Reports of Product prescribing issue with NIRSEVIMAB-ALIP
0.8%
of all NIRSEVIMAB-ALIP reports
0
Deaths
1
Hospitalizations

How Dangerous Is Product prescribing issue From NIRSEVIMAB-ALIP?

Of the 6 reports, 1 (16.7%) required hospitalization.

Is Product prescribing issue Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for NIRSEVIMAB-ALIP. However, 6 reports have been filed with the FAERS database.

What Other Side Effects Does NIRSEVIMAB-ALIP Cause?

Drug ineffective (173) Respiratory syncytial virus bronchiolitis (135) Bronchiolitis (83) Incorrect dose administered (80) Respiratory syncytial virus infection (76) Pyrexia (54) Cough (45) Respiratory syncytial virus test positive (36) Extra dose administered (30) Product storage error (30)

What Other Drugs Cause Product prescribing issue?

DUPILUMAB (1,715) POLYETHYLENE GLYCOL 3350 (1,439) LENALIDOMIDE (948) OXYCODONE (646) RIVAROXABAN (359) ACETAMINOPHEN\OXYCODONE (347) ETONOGESTREL (311) ACETAMINOPHEN\HYDROCODONE (298) CERTOLIZUMAB PEGOL (297) CABOZANTINIB S-MALATE (294)

Which NIRSEVIMAB-ALIP Alternatives Have Lower Product prescribing issue Risk?

NIRSEVIMAB-ALIP vs NITAZOXANIDE NIRSEVIMAB-ALIP vs NITISINONE NIRSEVIMAB-ALIP vs NITRAZEPAM NIRSEVIMAB-ALIP vs NITRENDIPINE NIRSEVIMAB-ALIP vs NITRIC

Related Pages

NIRSEVIMAB-ALIP Full Profile All Product prescribing issue Reports All Drugs Causing Product prescribing issue NIRSEVIMAB-ALIP Demographics